Table 3.
Subgroup analysis of any recurrence-free survival.
| Characteristic | Recurrence-Free Survival | |||
|---|---|---|---|---|
| N | No. Events | Median Survival (95% CI) (Months) | 1-Year Survival (95% CI) (%) | |
| Entire cohort | 319 | 153 | 15.2 (12.7–18.6) | 58.6 (52.2–65.7) |
| FDA-Indication | 79 | 28 | 17.1 (13.0-NA) | 65.6 (54.1-79.6) |
| E3b (urethroplasty failure) | 68 | 31 | 14.6 (12.7-NA) | 64.4 (53.1-78.0) |
| E3c (radiation) | 71 | 27 | 16.7 (12.0-NA) | 61.7 (49.0-77.7) |
| Treatment-naive (no prior treatments) | 90 | 26 | 24.5 (12.0-NA) | 59.9 (46.8-76.5) |
| S1 (bulbar strictures) | 214 | 82 | 14.9 (12.6-18) | 59.8 (52.2-68.5) |
| Stage IIC | 120 | 47 | 15.2 (12.1-NA) | 59.8 (50.0-71.5) |